Literature DB >> 6916711

Anomalous response of urinary kallikrein to deoxycorticosterone in Dahl salt-sensitive rats.

J P Rapp, R P McPartland, D L Sustarsic.   

Abstract

Previous evidence shows that salt-sensitive (S) rats have a net increase in plasma mineralocorticoid activity due to 18-hydroxy-11-deoxycorticosterone and decreased urinary kallikrein excretion compared to salt-resistant (R) rats. Since mineralocorticoids stimulate urinary kallikrein excretion, these results are inconsistent. This inconsistency was explained by the fact that, while R rats responded normally to treatment with deoxycorticosterone (DOC) by an increase in urinary kallikrein excretion, S rats showed no change in urinary kallikrein even when treated with 10 mg of DOC/day for 24 days. S and R rats responded identically to DOC with changes muscle electrolytes and relative hypertrophy of the renal distal tubule. Other measures of chronic mineralocorticoid response in S rats beside kallikrein were, therefore, intact. It was found that S rats were capable of responding to Na deficient diet with an increase in urinary kallikrein comparable to R rats. It was argued, therefore, that mineralocorticoid receptor mechanisms and distal-tubular cell responsiveness are intact in S rats. Mild glomerular and tubular scarring was found in S rats and the severity of renal lesions was increased by DOC treatment in S rats. These lesions correlated well with blood pressure and proteinuria. No such lesions were present in control or DOC treated R rats. It was suggested that failure of urinary kallikrein to respond to DOC in S rats may be a secondary phenomenon resulting from renal damage.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6916711     DOI: 10.1161/01.hyp.4.1.20

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  2 in total

1.  Regulation of rat urinary and renal kallikrein and prekallikrein by corticosteroids.

Authors:  Y Noda; K Yamada; R Igic; E G Erdös
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

Review 2.  A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Authors:  Makoto Katori; Masataka Majima
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.